Annals of Hematology

, Volume 91, Issue 6, pp 837–845 | Cite as

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group

  • Xiaoyang Li
  • Zhao Liu
  • Junning Cao
  • Xiaonan Hong
  • Jianmin Wang
  • Fangyuan Chen
  • Chun Wang
  • Shanhua Zou
  • Junmin Li
  • Zhixiang Shen
Original Article


The purpose of the study is to evaluate the 10 years follow-up of the efficacy in Chinese patients receiving cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) regimen as the initial treatment for diffuse large B cell lymphoma (DLBCL). We have retrospectively analyzed 437 patients with DLBCL who were newly diagnosed and received CHOP or R-CHOP regimen in six university hospitals and closely followed up after the completion of treatment. For all patients, there were significant differences between R-CHOP and CHOP for overall survival (OS) (median follow-up 86 months, 84.1% vs 70.2%, p = 0.018) and progression-free survival (PFS) (81.5% vs 66.7%, p = 0.015), while elder patients (>60 years old) received higher OS (median follow-up 66 months, 80.7% vs 53.0%, p = 0.011). But for younger patients (≤60 years old), the treatments with rituximab did not demonstrate a significant effect on OS (85.5% vs 79.4%, p = 0.428). In the R-CHOP group, International Prognostic Index (IPI) distinguished three risk groups instead of four risk groups. But in the CHOP group, IPI still distinguished four risk groups. Furthermore, for 212 of 437 patients diagnosed with extranodal involvement DLBCL, R-CHOP regimen provided a longer OS than CHOP regimen did (OS, 89.9% vs 71.7%, p = 0.014). Moreover, patients with extranodal lymphoma had a significant longer survival in rituximab era (OS, 89.9% vs 79.2% for extranodal and nodal, respectively; p = 0.048). The results of this large-scale study suggested that R-CHOP provided a greater survival benefit in the initial treatment of DLBCL. As for the patients with extranodal lymphoma, R-CHOP was also a good choice as first-line treatment. Extranodal disease seems to be an independent good prognostic factor in rituximab era.


Diffuse large B cell lymphoma Rituximab Long term Overall survival 



This work is supported by Shanghai Lymphoma Research Group. They are composed of Shanghai Ruijin Hospital, Shanghai Changhai Hospital, Shanghai Renji Hospital, Shanghai Zhongshan Hospital, Shanghai No. 1 People’s Hospital, and Shanghai Cancer Center. We would like to express appreciation to the research assistants at each institution for their diligence and attentiveness to detail and the outstanding clinical care delivered by all staffs.


  1. 1.
    Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511PubMedCrossRefGoogle Scholar
  2. 2.
    Korl AD, le Gessie S, Snijder S et al (2003) Primary extranodal non-Hodgkins lymphoma (NHL): the impact of alternative definition tested in the comprehensive cancer centre west population-based NHL registry. Ann Oncol 14:131–139CrossRefGoogle Scholar
  3. 3.
    Ji XL, Shen MS (1999) Extranodal lymphoma in China: an analysis of 943 cases. Chin J Canc 18(5):570–572Google Scholar
  4. 4.
    Friedberg JW (2008) Diffuse large b-cell lymphoma. Hematol Oncol Clin North Am 22(5):941–ix. doi: 10.1016/j.hoc.2008.07.002 CrossRefGoogle Scholar
  5. 5.
    Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMedCrossRefGoogle Scholar
  6. 6.
    Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell ymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391PubMedCrossRefGoogle Scholar
  7. 7.
    Gutiérrez-García G, Colomo L (2010) Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 51(7):1225–1232PubMedCrossRefGoogle Scholar
  8. 8.
    Zhang YN, Zhou XG, Zhang SH et al (2005) Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms. Zhonghua Bing Li Xue Za Zhi 34:193–197PubMedGoogle Scholar
  9. 9.
    Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, LyonGoogle Scholar
  10. 10.
    Sehn LH, Berry B et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861PubMedCrossRefGoogle Scholar
  11. 11.
    Wu H-J, Zhang Q-Y et al (2005) Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. Chin J Canc 24(12):1498–1502Google Scholar
  12. 12.
    Zhang H-Y, Huang Y, Shen T et al (2005) Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China—a multi-center randomized trial. Chin J Canc 24(12):1421–1426Google Scholar
  13. 13.
    Coiffier B, Thieblemont C, Van Den Neste E (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116(12):2040–2045PubMedCrossRefGoogle Scholar
  14. 14.
    Seki R, Ohshima K et al (2010) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol 91:258–266PubMedCrossRefGoogle Scholar
  15. 15.
    Sehn LH, Donaldson J et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23(22):5027–5033, Epub 2005 Jun 13PubMedCrossRefGoogle Scholar
  16. 16.
    Habermann TM, Weller EA, Morrison VA et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127PubMedCrossRefGoogle Scholar
  17. 17.
    National Comprehensive Cancer Network (2010) NCCN clinical practice guidelines in oncology: non-Hodgkin’s lymphoma. version 1Google Scholar
  18. 18.
    Horning SJ, Weller E, Kim K (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22(15):3032–3038PubMedCrossRefGoogle Scholar
  19. 19.
    Project TIN-HsLPF (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994CrossRefGoogle Scholar
  20. 20.
    Xia ZG, Li JM et al (2010) The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Ann Hematol 89(2):171–177, Epub 2009 Aug 11PubMedCrossRefGoogle Scholar
  21. 21.
    Hermine O, Haioun C, Lepage E et al (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 87:265–272PubMedGoogle Scholar
  22. 22.
    Ichikawa A, Kinoshita T, Watanabe T et al (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534PubMedCrossRefGoogle Scholar
  23. 23.
    Sehn LH, Berry B, Chhanabhai M et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861PubMedCrossRefGoogle Scholar
  24. 24.
    Krol A, le Cessie S, Snijder S et al (2003) Primary extranodal non-Hodgkin’s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 14(1):131–139PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Xiaoyang Li
    • 1
  • Zhao Liu
    • 1
  • Junning Cao
    • 2
  • Xiaonan Hong
    • 2
  • Jianmin Wang
    • 3
  • Fangyuan Chen
    • 4
  • Chun Wang
    • 5
  • Shanhua Zou
    • 6
  • Junmin Li
    • 1
  • Zhixiang Shen
    • 1
  1. 1.Department of HematologyRuijin Hospital Affiliated to Shanghai Jiaotong University School of MedicineShanghaiPeople’s Republic of China
  2. 2.Department of Medical OncologyFudan University Shanghai Cancer centerShanghaiChina
  3. 3.Changhai HospitalShanghaiChina
  4. 4.Renji HospitalShanghaiChina
  5. 5.Shanghai No. 1 People’s HospitalShanghaiChina
  6. 6.Zhongshan HospitalShanghaiChina

Personalised recommendations